DSPACE

https://dspace.org/

Surgical site infection at a tertiary academic hospital in Johannesburg: a one year audit

Barbakh, Mohammed K E

2022
https://hdl.handle.net/10539/35271

Downloaded from a DSpace repository. https://dspace.org/

SURGICAL SITE INFECTION AT A TERTIARY ACADEMIC HOSPITAL IN JOHANNESBURG: A ONE YEAR AUDIT

Mohammed K E Barbakh

Student number: 1578236

Department of General Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

E-mail address: mohamekhaled12@yahoo.com

Cell: +27767707548

A Research Report (in the format of a "submissible" paper already published in the Journal of Surgery) submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial fulfilment of the requirements for the degree of Master in Medicine

Johannesburg 2020

Co-authors/Supervisors

Prof Thifheli Luvhengo (MBBCh, FCS (SA))

Department of General Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

E-mail address: thifhelimbilu.luvhengo@wits.ac.za

Prof Adelin Muganza (MBBCh, FCS (SA))

Department of General Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

E-mail address: amuganza@gmail.com

Dr Marietha Nel (BSc, BScHon (Pharmacol), MSc, PhD)

Department of General Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

E-mail address: marietha.nel@wits.ac.za

Declaration

I, Mohammed Barbakh, declare that this Research Report in the format of a submissible paper is my own, original work. It is submitted for the Degree of Master of Medicine in Surgery at University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at University of the Witwatersrand or at any other university.

13th day of June 2022 (Johannesburg)

Signature:

Dedication

This dissertation work is dedicated to my family, friends and colleagues. To my parents Khaled and Amina your prayers always work for me. A special dedication to my wife Nuha who remains the most selfless person I have ever seen, for her continued motivation and support throughout my studies. Your patience and encouragement are beyond measure. I thank the Almighty for making her part of my life. I would not have achieved this degree without your encouragement.

To my lovely sons Mousa, Yousef and Ibrahim who continuously cheered me up and gave me promising words that kept me ongoing. To my mentor long before being my supervisor, Professor Luvhengo, for his unlimited and unconditional support.

To Dr Arain and Dr Monareng for their support. To the Wings of Mercy Organization and Mr Moeen Elhaddad for their kind support.

Lastly, a special appreciation to my colleagues and friends for unceasingly inspiring and believing in me when I doubted myself, your reassuring words pushed me to keep on going.

Oral presentations arising from this study:

1- 2019 BERT MYBURGH RESEARCH FORUM
2- 48th SURGICAL SOCIETY OF SOUTH AFRICA (SRSSA) ANNUAL VIRTUAL MEETING in 2021.

Abstract

Introduction: Surgical site infection (SSI) occurs during the first 30 days after surgery and affects either the incision or deep tissue at the site of operation. Surgical site infection accounts for approximately 38% of hospital-acquired infections globally and is associated with increased length of hospitalization and mortality, and therefore increased cost of health care. The type of causative organisms in SSI is influenced by among others the type of surgery. Frequently isolated organisms in SSI include *Escherichia coli*, coagulase-negative *Staphylococci*, *Enterococcus species* and *Staphylococcus aureus*.

Aim: The aim of this study was to determine the incidence of SSI, causative organisms and factors which were associated with its occurrence at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH).

Methods: This was a retrospective review of records of patients who were operated over the 12 months and subsequently developed SSI. Data of patients who developed SSI were extracted from records of weekly morbidity and mortality meetings of the Department of Surgery, which are captured on the Research Electronic Data Capture (REDCap). Data retrieved included demographic information, co-morbidities, nature of surgery, class of SSI and microscopy, culture and sensitivity results and overall outcome including the length of hospital stay. Descriptive, bivariate and multivariate analysis of the data was performed.

Results: During the study period 3005 surgical procedures were performed of which 46.8% were elective operations. A total of 147 records of patients who developed SSI were found. The incidence of reported SSI was 4.8% (147/3005) with 72.6% (93/147) occurring in males. The mean age of all the patients who developed SSI was 47.3 ± 17.21 years (range: 16-82 years). *E. coli* and *P. aeruginosa* from 44% (36/82) and 29.3% (24/82), respectively. Of patients who developed SSI, 30.5% (39/128) had diabetes mellitus, 21.9% (28/128) had hypertension and 18.8% (24/128) had both diabetes and hypertension while 15.6% (20) of the patients were known to be HIV positive.

Conclusion: The overall rate of SSI in the surgical patients was 4.8%. Majority of SSI occurred males. The two most commonly cultured organisms in patients who developed SSI were *E. coli* and *P. aeruginosa*. Thirty-one percent of the patient who were diagnosed with SSIs had diabetes mellitus.

Word count: 336

Keywords: Classification, Co-morbidities, Diabetes Mellitus, Gender, HIV, Surgical Site Infection.

Acknowledgments:

On completion of this report, I would like to thank the following persons and institution:

My supervisors Prof Thifheli Luvhengo, Dr Marietha Nel and Prof Adelin Muganza for their support and guidance.

A special thanks to Mr Tamer Almassri the former officer at the Embassy of the State of Palestine, Pretoria and Mr Hassona Aldramly and Mr Bassam Elhussiny from the Embassy of the State of Palestine for their valuable support and advice.

My family for their ongoing support.

Table of Contents

Title page	i
Declaration	ii
Dedication	iii
Oral presentations arising from this study	iv
Abstract	v
Acknowledgements	vii
Table of Contents	viii
List of Figures	ix
List of Tables	x
List of Abbreviations	xi
Introduction	1
Methods	2
Results	3
Discussion	9
Conclusion	10
References	11
Appendix 1: Approved research protocol	14
Appendix A: Data collection sheet	25
Appendix B: CMJAH CEO Letter of approval	26
Appendix C: Ethics clearance certificate	27
Appendix D: CDC definition of ISS	28
Appendix 2: Turnitin report	29
World Journal of Surgery instructions to authors	31
Letter to the editor	41
Author contribution statement and agreement of co-authors	43

List of Figures

Figure 1: Antimicrobial sensitivity of cultured *E. coli*

Figure 2: Drug sensitivity profile for *P. aeruginosa*

Figure 3: Sensitivity profile for *K. pneumoniae*

Figure 4: Sensitivity profile for *S. aureus*

Figure 5: Sensitivity profile for *A. baumannii*

List of Tables

Table 1: Demographic characteristics of patients who developed SSI

Table 2: Pre-operative and post-operative clinical and laboratory findings in patients who developed SSI

Table 3: Options used for management of SSI

Table 4: Culture results in patients who developed SSI

Table 5: Breakdown of microorganisms cultured in patients who developed SSI according to types of operation

List of Abbreviations

A. baumannii	*Acinetobacter baumannii*
CDC	Centers for Disease Control and Prevention
CMJAH	Charlotte Maxeke Johannesburg Academic Hospital
CRP	C-reactive protein
DCS	Data collection sheet
DM	Diabetes mellitus
E. coli	*Escherichia coli*
K. pneumonia	*Klebsiella pneumonia*
P. aeruginosa	*Pseudomonas aeruginosa*
PCT	Procalcitonin
S. aureus	*Staphylococcus aureus*.
SSI	Surgical site infection
WCC	White cell count

Introduction

Surgical site infection (SSI) is an infection of the skin, soft tissues, organs or anatomical spaces following an invasive procedure. Included are infections, which occur within 30 days following the procedure and even up to a year if the operation included insertion of a prosthetic device if an implant is in place. The definition of SSI does not include burn wounds, circumcision, episiotomies or stitch abscesses.

Surgical site infections (SSIs) account for approximately 38% of all hospital acquired infections globally [1]. Surgical site infection is the most commonly reported type of nosocomial infection globally and accounted for 19.6% of all nosocomial infections in Europe in 2011-2012 and which was higher than the rate of pneumonia and urinary tract infections at 19.4% and 19.0%, respectively [2]. Seventy-five percent of the mortalities in patients who develop SSI are directly related to the SSI [3].

Surgical site infection is classified into incisional and organ or space infections (1). Incisional site infection is further sub-classified into superficial i.e. an infection which limited to skin and subcutaneous tissue (1). Risk factors of SSI are divided into patient-related (preoperative), procedure-related (perioperative), and postoperative categories. The patient-connected risk factors for SSI are categorized as either modifiable or non-modifiable (2). The modifiable factors include diabetes mellitus, obesity, smoking and length of preoperative hospitalization (1). An example of a non-modifiable risk factor for SSI is the age of a patient. Among the risk factors which are related to the operation is the class of a surgical wound, organ site and the length of the surgery. Some of the postoperative risk factors for SSI are blood transfusion and poor glycaemic control (2).

Surgical site infection is frequently associated with increased morbidity, mortality and length of hospital stay. The development of SSI increases the clinical and financial burden of surgery. Surgical site infection increases the work load of the healthcare professionals and has a negative impact on patient's outcome [2]. The economic impact of SSI is mainly due to an increase in the length of hospitalization, additional diagnostic tests, antimicrobial use and dressings (2). Reoperation in necessary in some of the patients who develop SSI (2). Badia and colleagues showed that patients who developed SSIs incurred twice the medical cost compared to patients who did not develop SSIs (2). In the same study by Badia and the team showed that the length of

stay of patients who developed SSI was double the number of days of patients who did not develop SSI.

The reported rate of occurrence of SSIs in sub-Saharan Africa ranges from 6.8% to 26% [4]. The aim of this study was to determine the rate of occurrence of SSI at a tertiary academic hospital in the Gauteng Province of South Africa. Furthermore, the factors which were prevalent in patient who developed SSI were studied.

Methods

Permission to conduct the study permission was obtained from the Human Research Ethics Committee of University of the Witwatersrand (M180945) and the CEO of CMJAH. This was a retrospective observational study based on audit of the records of weekly morbidity and mortality (M+M) meeting of the Department of Surgery. The meeting is run on REDCap. Postoperative complications are classified using the modified Clavien-Dindo classification of postoperative complications (Add reference). Additional information was obtained from theatre records, patients' file and microbiology results. Data retrieved included demographic information, co-morbidities, nature of surgery, class of SSI and microscopy, culture and sensitivity (MC&S) results and overall outcome including the length of hospital stay.

The records of all patients who were operated on and subsequently developed SSI during the study period were reviewed. Although the original plan was to conduct the study over a 2-year period the subjects for the present study were all patients who had an operation at CMJAH between the 1st of July 2017 and 30th of June 2018, and subsequently developed SSI, as defined by the CDC (Appendix D). The patients included in the study were the individuals who were declared to have developed SSI by the surgical units during the M+M meeting. Records of patients who were re-admitted for SSI following an operation before the period of study, patients on immune-suppressants, patients whose records were incomplete and patients with infection of another area not related to the area of operation e.g. urinary tract infection (UTI), were excluded from the study.

Each case was given an individual study number on the DCS without recording any personal identifiers. Information was transcribed from the anonymous patient DCS to an Excel spreadsheet using the patient's study only. A separate list of patient study numbers with patient identifiers recorded was kept in a safe and user name protected

electronic file, only accessible to the principal investigator, to ensure anonymity of the patients.

Data were analysed using the statistical programme Stata v13.1 (College Station, Texas). Continuous data were summarized by using the mean plus standard deviation when data were normally distributed, and the median and inter-quartile range (IQR) when the data were not normally distributed as determined using the Shapiro Wilk test for data distribution. The paired t-test was used for comparison of findings with normally distributed continuous data, and the Wilcoxon signed rank test if not normally distributed. Categorical findings were compared analysed by calculating frequency and percentage and using the chi-square test and the Fisher's exact test. The level of significance was set at a p-value <0.05.

Results

A total of 147 cases of SSI among 3 005 surgeries were recorded in REDCap over a one-year period. Less than half, 1 406 (46.8%) of the operations were elective operations. The rate of SSI was 4.8%. Of these 147 cases, two patients had a kidney transplant and were on immune-suppressants and hospital files for 17 patients could not be traced, thus 19 cases were excluded. Of the remaining 128 patients, 72.7% (96/128) of the reported cases was in male patients and 63.3% (81/128) of the SSIs developed in patients who had emergency surgical procedures. The mean age of the patients who developed SSI was 47.3 ± 17.21 years. Around 44.5% (57/128) the SSIs were superficial SSIs (Table 1).

Table 1: Demography, number of co-morbidities and type of SSIs in patients who developed SSI (n = 128)

Parameter	**Finding**
Emergency to Elective Ratio	81/47.
Male to Female Ratio	93/35.
Mean age in years	47.3 ± 17.21.
Associated co-morbidities (%)	Yes: 111(86.7%). No: 17(13.3%).
Types of SSI (%)	Superficial: 57 (44.5%). Deep: 15 (11.7%). Organ space: 56 (43.8%).

The rate of occurrence of SSI in elective cases was 5.1% (81/1 599) and in emergency patients it was 3.3% (47/1 406) out of the total of 3005 patients. Among the patients who developed SSI, 30.5% (39/128) had diabetes mellitus, 21.9% (28/128) had hypertension and 18.8% (24/128) had both diabetes and hypertension while 15.5% (20/128) were known to be HIV positive. The mean pre-operative body temperature in patients who developed SSI was 37.2 ± 0.36 ^{o}C compared to 37.7 ± 0.35 ^{o}C post-operatively, and the difference was statistically significant (Table 2).

Table 2: Pre-operative and post-operative clinical and laboratory findings in patients who developed SSI (n = 128)

Parameter	**Findings**		
	Pre-operative	Post-operative	p-value
Mean body temperature	37.2 ± 0.36^{o}C	37.7 ± 0.35^{o}C	0.0150
Mean white cell count	11.3 ± 5.9	18.5 ± 8.6	0.0010
Mean CRP	86.1 ± 11.8	229.5 ± 111.1	< 0.00001
Mean blood glucose	9.6 ± 3.1	11.9 ± 3.9	0.0042

Of the patients who developed SSI 45.3% (58/128) had open surgical interventions whereas a percutaneous drainage was done in 10.2% (13 cases), and one patient was treated with intravenous (IV) antibiotics without any other intervention (Table 3).

Table 3: Options used for management of SSI (n = 128)

Intervention	**Number (%)**	**Cumulative %**
Relook procedure	58 (45.3%)	45.3%
Removal of stitches or clips	47 (36.7%)	82.0%
Percutaneous drainage	13 (10.2%)	92.2%
Debridement	5 (3.9%)	96.1%
Wound irrigation	3 (2.3%)	98.4%
Wound dressings	1 (0.8%)	99.2%
Intravenous antibiotics only	1 (0.8%)	100%
TOTAL	128	100%

Sixty-four percent (64.1%: 82/128) of the patients who developed SSI had positive microscopy culture and sensitivity (MC&S) results. In 28.1% (36/128) of the cases culture results showed *E. coli* (Table 4). Thirty-two percent (41/128) of the MC&S results showed more than one organism.

Table 4: Culture results in patients who developed SSI (n = 82)

Organism isolated	**Number (%)**
E.coli	36 (43.9%)
P. aeruginosa	24 (29.3%)
K. pneumoniae	12 (14.6%)
S. aureus	11 (13.4%)
A. baumannii	8 (9.7%)
E. faecum	8 (9.7%)

Colorectal procedures accounted for 37/82 of the positive culture results and 40/82 from other forms of laparotomy. Of the colorectal procedures, 37.8% (14/37) of SSIs cultured, were positive for *E. coli* (Table 5).

Table 5: Breakdown of microorganisms cultured in patients who developed SSI according to type of operation

Original surgical procedure	***E. coli***	***P. aeruginosa***	***S. aureus***	***A. baumannii***	***E. faecium***	***K. pneumonia***	***E. faecalis***	**Total**
Laparotomy	15	8	4	5	2	3	3	40
Colorectal	14	6	1	2	3	7	4	37
Vascular	2	2	1	-	1	-	-	6
Amputation	-	2	-	1	-	1	1	5
Hernia	-	2	1	-	-	1	-	4
Breast	-	1	3	-	-	-	-	4
Appendi-cectomy	2	1	-	-	-	-	-	3
Other	3	1	-	-	-	-	-	4

Around 47.2% (17/36) of the *E. coli* cultured were sensitive to amoxicillin/clavulanic acid (Augmentin) while 22.2% (8/36) were sensitive to 3rd generation cephalosporins (Figure 1).




Figure 1: Antimicrobial sensitivity of cultured *E. coli* (n = 36).

*Tazocin = Piperacillin/Tazobactam

Forty-six percent (11 /24) of *P. aeruginosa* were sensitive to piperacillin/tazobactam (Tazocin) (Figure 2).




Figure 2: Drug sensitivity profile for *P. aeruginosa*

In the case of *K. pneumoniae,* three strains (25%), showed susceptibility to Amikacin, two strains (16.7%) were sensitive to either Tazocin or to Imipenem and one strain was sensitive to Cefepime, Colistin, Augmentin, Ertapenem and to Ceftriaxone (Figure 3).




Figure 3: Sensitivity profile for *K. pneumoniae*

In the case of *S. aureus,* eight strains (72.7%), showed susceptibility to Cloxacillin, and three strains (27.3%) were sensitive to Vancomycin (Figure 4).




Figure 4: Sensitivity profile for *S. aureus.*

The *A. baumannii* strains showed sensitivity to colistin in two strains (25%) and 12.5% (1/8) showed sensitivity to either ciprofloxacin, ceftazidime, amikacin, Augmentin, ceftriaxone and gentamicin.




Figure 5: Sensitivity profile for *A baumannii*

Among SSIs patients there were two mortalities, 49.2% (63/128) of the patients needed at least one surgical intervention, 10% (13/128) had a pigtail for intra-abdominal collections. The median of the length of hospital stay was 18 days, with no difference between different types of wounds. The length of stay was 22 days among the patients who developed organ/space SSI. Two patients (1.6%: 2/128) who developed SSI died. Twenty-eight percent (36/128) required re-admission.

Discussion

This study revealed a rate of SSIs of 4.8%, which is comparable to the incidence of SSIs reported by Nair *et al.,* in the Northern Cape Province of South Africa [5]. The relatively low rate of SSI in South Africa are similar to figures reported in Norway (4.6%) [6] and Switzerland (4%) [7]. In contrast the rate of occurrence of SSI across the African continent is high, For example the rate of SSI which was reported from Nigeria ranged from 15 to 27% [8,9] while from Ethiopia 19.1% [10,11] and in Tanzania 26.0% [12]. However, the SSI reported rates from countries across the world may not be

comparable as patients' attributes, wound classifications and diagnostic approach could have been different.

A higher rate of occurrence of SSI in patients who were younger than 40 years is not different to findings from prior studies [13]. Two-thirds of the patients in our study developed SSI after elective surgical interventions, which might have influenced the results. The rate of occurrence of SSI is also influenced by nutritional status of a patient, the level of immunity and comorbid illnesses such as HIV/AIDS or diabetes mellitus [14-17].

Patients with SSIs are much more likely to spend extra days in the clinic/hospital in contrast to patients without SSIs. This observation is in line with a number of other reports [2,18–20]. The mean of the length of stay in this study was 18 days, which is within the ranges found in other studies (3 to 23 days), and similar to the Whitehouse et al*.,* study (19 days) [21].

The present study retrospectively analysed the plasma concentration of the white cell count (WCC) and C-reactive protein (CRP) regarding their sensitivity and specificity for detecting perioperative infections. Regardless of the type of operation or the type of SSI that developed, the study showed a 100% increase in CRP, and in 85.1% of the patients the WCC was high. Similar findings were reported in two other studies [22,23].

Although, the procalcitonin test (PCT) is commonly used as a diagnostic marker of sepsis [24], and has been confirmed to be a more accurate marker for the recognition of early postoperative infection after cardiac and intestinal surgeries when compared with standard laboratory parameters, such as CRP and WBC [25], in this current study the WCC and CRP were still used as indicators of infection.

In this current study approximately 44% of SSIs were classified either as superficial or organ/space SSIs, while most other studies revealed that superficial SSIs are the most frequently occurring type [26]. In contrast, results found by Poulsen *et al.*, indicated that more than 30% of SSIs are organ/space SSIs [27].

The most common microorganisms cultured in this study were gram-negative bacteria and these results are similar to a study done by Golzarri and colleagues in a 7-year retrospective review [28], while most of the other studies revealed a predominance of gram-positive microorganisms as the main cause of SSI [28-31].

Of importance is that this study provides standard information on the event of SSIs at the hospital and it may serve as a helpful tool in decision making and in assigning restricted funds in addressing SSIs and hospital acquired infections in general.

Conclusions

The overall rate of SSI in the surgical patients was 4.8%. Majority of SSI occurred males. The two most commonly cultured organisms in patients who developed SSI were *E. coli* and *P. aeruginosa*. Thirty-one percent of the patient who were diagnosed with SSIs had diabetes mellitus.

Limitations of the study

As a retrospective study, it lacked the comparison of a control group. A cause-and-effect relationship could not be determined. The study relied on the quality of documentation, and sometimes doctors and/or nurses do not report the incidence. Furthermore, complications sometimes occur on discharge and are not noticed at the Out Patients Department. Patients not returning to our hospital but going to another hospital for whatever reason may also have impacted on our study. Another but substantial limitation was that it was only a one-year study at one hospital only.

References

1. Bull AL, Worth LJ, Spelman T, et al (2017) Antibiotic prescribing practices for prevention of surgical site infections in Australia: increased uptake of national guidelines after surveillance and reporting and impact on infection rates. Surg Infect 18:834–840.

2. Badia JM, Casey AL, Petrosillo N (2017) Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect 96:1–15.

3. Anderson D and Sexton D (2019). *UpToDate*. [online] Uptodate.com. Available at: https://www.uptodate.com/contents/overview-of-control-measures-for-prevention-of-surgical-site-infection-in-adults?

search=surgical%20site%20infection&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 [Accessed 12 Nov. 2019].

4. Ngaroua, Ngah JE, Bénet T, et al (2016) Incidence of surgical site infections in sub-Saharan Africa: systematic review and meta-analysis]. Pan Afr Med J. 24:171.

5. Nair A, Steinberg WJ, Habib T (2018). Prevalence of healthcare-associated infection at a tertiary hospital in the Northern Cape Province, South Africa. South Afr Fam Pract 60:162–167.

6. Eriksen HM, Iversen BG, Aavitsland P (2005) Prevalence of nosocomial infections in hospitals in Norway, 2002 and 2003. J Hosp Infect 60:40–45.

7. Harbarth S, Ruef C, Francioli P, et al (1999) Nosocomial infections in Swiss university hospitals: a multi-centre survey and review of the published experience. Swiss-Noso Network. Schweiz Med Wochenschr 129:1521–1528.

8. Olowo-Okere A, Ibrahim YKE, Olayinka BO, et al (2019). Epidemiology of surgical site infections in Nigeria: A systematic review and meta-analysis. Niger Postgrad Med J 26:143–151.

9. Olowo-Okere A, Ibrahim YKE, Sani AS, et al (2018) Occurrence of Surgical Site Infections at a Tertiary Healthcare Facility in Abuja, Nigeria: A Prospective Observational Study. Med Sci 6:60.

10. Billoro BB, Nunemo MH, Gelan SE, et al (2019) Evaluation of antimicrobial prophylaxis use and rate of surgical site infection in surgical ward of Wachemo University Nigist Eleni Mohammed Memorial Hospital, Southern Ethiopia: prospective cohort study. BMC Infect Dis 19:298.

11. Dessie W, Mulugeta G, Fentaw S, et al (2016) Pattern of Bacterial Pathogens and Their Susceptibility Isolated from Surgical Site Infections at Selected Referral Hospitals, Addis Ababa, Ethiopia. Int J Microbiol. 2016;2016:1–8.

12. Mawalla B, Mshana SE, Chalya PL, et al (2011) Predictors of surgical site infections among patients undergoing major surgery at Bugando Medical Centre in Northwestern Tanzania. BMC Surg 11:21.

13. Gardner EM and Murasko DM, (2002) Age-related changes in Type 1 and Type 2 cytokine production in humans. Biogerontology 3:271–290.

14. Latham R, Lancaster AD, Covington JF, et al (2001) The Association of Diabetes and Glucose Control With Surgical-Site Infections Among Cardiothoracic Surgery Patients. Infect Control Hosp Epidemiol 22:607–612.

15. Zerr KJ, Furnary AP, Grunkemeier GL, et al (1997) Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 63:356–361.

16. Cheadle WG, (2006) Risk factors for surgical site infection. Surg Infect 7:7-11.

17. Delgado-Rodríguez M, Medina-Cuadros M, Martínez-Gallego G, et al (1997) Total cholesterol, HDL-cholesterol, and risk of nosocomial infection: a prospective study in surgical patients. Infect Control Hosp Epidemiol 18:9–18.

18. Schweizer ML, Cullen JJ, Perencevich EN, et al (2014) Costs Associated With Surgical Site Infections in Veterans Affairs Hospitals. JAMA Surg 149:575-581.

19. Vegas AA, Jodra VM, Garcia ML (1993) Nosocomial infection in surgery wards: a controlled study of increased duration of hospital stays and direct cost of hospitalization. Eur J Epidemiol 9:504–510

20. Purba AKR, Setiawan D, Bathoorn E, et al (2018) Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics. Front Pharmacol 9:776.

21. Whitehouse JD, Friedman ND, Kirkland KB, et al (2002) The Impact of Surgical-Site Infections Following Orthopedic Surgery at a Community Hospital and a University Hospital Adverse Quality of Life, Excess Length of Stay, and Extra Cost. Infect Control Hosp Epidemiol 23:183–189.

22. Kang KT, Son DW, Lee SH, et al (2017) Variation of C-Reactive Protein and White Blood Cell Counts in Spinal Operation: Primary Fusion Surgery Versus Revision Fusion Surgery. Korean J Spine 14:66–70.

23. Ortega-Deballon P, Radais F, Facy O, et al (2010) C-Reactive Protein Is an Early Predictor of Septic Complications After Elective Colorectal Surgery. World J Surg 34:808–814.

24. Vijayan AL, Vanimaya, Ravindran S, et al (2017) Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care 5:51-7.

25. Omar J, Isa S, Ismail TST, et al (2019) Procalcitonin as an Early Laboratory Marker of Sepsis in Neonates: Variation in Diagnostic Performance and Discrimination Value. Malays J Med Sci 26:61–9.

26. Medeiros AC, Tertuliano AN, Azevedo GD, et al (2005) Surgical site infection in a university hospital in north east Brazil. Brazilian J Infect Dis 9:310-314.

27. Poulsen KB, Bremmelgaard A, Sørensen AI, et al (1994) Estimated costs of postoperative wound infections: A case-control study of marginal hospital and social security costs. Epidemiol Infect 113:283–295.

28. Hernaiz-Leonardo JC, Golzarri MF, Ostrosky-Frid M, et al. (2017) Microbiology of surgical site infections in patients with cancer: A 7-year review. Am J Infect Control. 45(7):761–766.

29. Mundhada A and Tenpe S (2015) A study of organisms causing surgical site infections and their antimicrobial susceptibility in a tertiary care Government Hospital. Indian J Pathol Microbiol 58:195-200.

30. Owens CD, Stoessel K (2008) Surgical site infections: epidemiology, microbiology and prevention. J Hosp Infect 70:3–10.

31. Matinyi S, Enoch M, Akia D, et al (2018) Contamination of microbial pathogens and their antimicrobial pattern in operating theatres of peri-urban eastern Uganda: a cross-sectional study. BMC Infect Dis 18(1):460.

Appendix 1: Approved research protocol

Corrected protocol with list of corrections attached as the 2nd last page, and the plagiarism declaration as the last page.

Faculty of Health Sciences, Postgraduate Office
Phillip V Tobias Building, 2nd Floor
Cnr York & Princess of Wales Terrace, Parktown 2193
Tel: (011) 717 2463/2125 | Fax: (011) 717 2119
Email: palesa.khumalo@wits.ac.za/thando.mbolekwa@wits.ac.za

CANDIDATE'S SURNAME: Barbakh	FIRST NAME: Mohammed	STUDENT NUMBER: 1578236
CURRENT QUALIFICATIONS: MBCHB		
TEL:	CELL:0767707548	E-MAIL: mohamekhaled12@yahoo.com / FAX:
DEGREE FOR WHICH PROTOCOL IS BEING SUBMITTED: MMed		
PART-TIME OR FULL-TIME: Full-time		
FIRST REGISTERED FOR THIS DEGREE:	TERM : January	YEAR:2016
DEPARTMENT: General surgery		
TITLE OF PROPOSED RESEARCH: Surgical site infection at a tertiary academic hospital in Johannesburg: 2 year audit		
CANDIDATE'S SIGNATURE:		DATE:
SPERVISOR 1(NAME& SURNAME): Prof. Adelin Muganza		30 % Supervision
SUPERVISOR'S QUALIFICATIONS: MD, FRCSI, FCS (SA)		
SUPERVISOR'S DEPARTMENT: General surgery		
SUPERVISOR'S ADDRESS / TEL / E-MAIL: amuganza@gmail.com		
SUPERVISOR 2(NAME& SURMANE): Dr. Marietha Nel		30 % Supervision
SUPERVISOR'S QUALIFICATIONS: MSc, BSc, PhD		
SUPERVISOR'S ADDRESS / TEL / E-MAIL: marietha.nel@wits.ac.za		

SUPERVISOR 3(NAME& SURNAME): Prof. Thifhelimbilu Luvhengo	40 % Supervision
SUPERVISOR'S QUALIFICATIONS: MBChB, FCS (SA)	
SUPERVISOR'S ADDRESS / TEL / E-MAIL: Thifhelimbilu.Luvhengo@wits.ac.za	
SYNOPSIS OF RESEARCH: A retrospective study based on audit of Morbidity and Mortality and RedCap records To determine the incidence and associated factors in patients who develop surgical site infections (SSIs) at CMJAH, and to determine the demographic and clinical pathology findings in patients who developed SSIs at CMJAH.	
ETHICS PENDING: Y ETHICS APPROVED: Y (circle appropriate symbol)	IF Y SUPPLY ETHICS CLEARANCE No:
SIGNATURE OF SUPERVISOR/S:	.....
SIGNATURE PG OFFICE STAFF	REGISTERED YES..... NO.....
	STAMP

Protocol

Surgical Site Infection at a Tertiary Academic Hospital in Johannesburg: a 2 -ear Audit

Candidate: Dr. Mohammed Barbakh

Student Number: 1578236

Course: MMed (Surg)

Supervisors

1. Prof. Muganza A: 30%
2. Dr. Nel M: 30%:
3. Prof. Luvhengo TE: 40%

Introduction

Definition: Surgical site infections (SSIs) are infections of the skin, tissues, organs, or spaces exposed by surgeons during performance of an invasive procedure, occurring within 30 days of the operation if no implant is left in place or within 1 year if an implant is in place. The definition of SSI does not include burn wounds, circumcision, episiotomies or stitch abscesses[1].

Incidence: Surgical site infection accounts for around 38% of hospital acquired infections globally[2.] It is the most commonly reported type of nosocomial infections and accounted for up to 19.6% of all nosocomial infections in Europe in 2011-2012, followed by pneumonia and urinary tract infections at rates of 19.4% and 19.0%, respectively[3]. In more than 75% of patients who develop SSI and die in the postoperative period, the mortality is directly related to the SSI[4].

Although no incidence/prevalence data on SSIs in general surgery are available for South Africa, the impact of SSIs in sub-Saharan Africa ranges from 6.8% to 26% with predominance in general surgery. This is in part the reason for embarking on this study although it will only be over a 2-year period and at one hospital, the study will give some insight regarding the incidence of SSI in South Africa.

Classifications: Surgical site infection is classified into incisional and organ or space infections. Incisional site infection is further sub-classified into superficial i.e. infections limited to skin and subcutaneous tissue[5].

Risk factors: Risk factors of SSI may be systemic or local. Advanced age (generally ≥ 65years) is a distinct risk factor for adverse outcomes of infection[6] related to immune senescence and an increased incidence of nosocomial infection.

Furthermore, hyperglycemia in the setting of diabetes mellitus and temporary hyperglycemia induced by stress response, are also associated with an increased risk of surgical site infection [7,8,9,10]. Other systemic host factors which contribute significantly to the risk of surgical site infection include obesity, malnutrition, HIV, AIDS[11], advanced malignancies, organ system failure, hypocholesterolaemia and patients on immunosuppressive drugs[12].

Local factors which influence the development of SSI include poor skin preparation, prolonged operation time, improper surgical technique such as leaving a large dead space, haematoma, overuse of cautery or rough tissue handling and the presence of a foreign body[13].

Perioperative strategies such as shaving and choice of solution for skin preparation also influence the incidence of SSI. Darouiche *et al.,* (2010), have recommended chlorhexidine for surgical skin preparation to prevent SSI[14]. Supporting this recommendation is a study done by Milestone which showed that chlorhexidine is superior to povidone-iodine solution for skin preparation for vascular catheter insertion[15].

Skin closure of a contaminated incision is believed to increase the risk of SSI. Unfortunately, no large enough studies are available to determine if SSI rate is influenced by the choice of wound closure techniques available to surgeons. Interestingly, Chantip *et al.,* (2017) found that early primary closure of the surgical wound in complicated appendicitis cases have a lower incidence of superficial SSI than delayed primary closure, however, this finding did not reach statistical significance[16]. Minimal invasive surgery is associated with a decreased incidence of SSI[17].

As incorporated in the National Nosocomial Infections Surveillance System (NNIS), and its successor program, the National Healthcare Safety Network (NHSN), the most predictable factors for the development of SSI is the American Society of Anesthesiologists Class 3 procedures or higher and prolonged operative times [18,19,20].

The type of surgical procedure affects the rate of SSI. As such, abdominal surgery has the highest risk for SSI even following 'clean' surgery[4]. Even endovascular procedures are not immune to SSI as it was found by Aziz *et al*., (2017) that SSI is indeed one of the causes for readmission of patients who underwent endovascular aortic repair [21]. Although the use of antibiotic prophylaxis lowers the incidence of SSI for surgical procedures including breast reduction and hernia repair[22,23], the different causal organisms need to be recognised and treated appropriately. Furthermore, because of the huge importance of prevention of SSIs many recommendations were made by various health organizations and these recommendations are still undergoing modulations by adding and deleting some of the components[23].

Signs and symptoms: As per The Centers for Disease Control and Prevention (CDC) the signs of SSI are general and local. They include pain, tenderness, fever, increase heart rate, localized swelling, redness in the wound area and discharge from the

wound[24]. In spreading necrotizing infection crepitus may be elicited. In blood tests we will find an increase in septic markers such as C- reactive protein and white cell count[24].

Causative organisms: The normal skin flora that is introduced through the incision during surgery cause most of the SSIs. Therefore, the most common pathogens in SSI are gram-positive cocci (*Staphylococcus epidermidis, S. aureus,* and *Enterococcus* spp)[25] which are the three most common organisms found normal skin.

Treatment: The basic treatment of wound infection is to re-open the wound and allow it to drain. In a mild infection, a simple dressing change will be adequate, without any antibiotics needed, whereas for a clean wound, 1st generation cephalosporin may be given. However, if the infection is severe, 3rd generation cephalosporin or a quinolone plus clindamycin or metronidazole, or piperacillin – tazobactam alone is recommended[26]. Importantly, antimicrobials alone are not sufficient for severe SSI. Invasive and necrotizing infection requires aggressive debridement as well. Antibiotics are stopped as soon as local inflammation and systemic signs of infection have resolved and there is no gross evidence of necrotic tissue [26].

For organ or space SSI, treatment consists of IV fluids for resuscitation, elimination of the source of infection, e.g. laparotomy and closure of perforated viscus, removal of necrotic material and appropriate antibiotic therapy[26].

Financial impact: Surgical site infection is frequently associated with increased morbidity, mortality and hospitalization. In addition, the development of SSI increases the clinical and financial burden of surgery. Indeed, SSI causes an increase in the already overburdened economic load of the health system especially in South Africa. It increases the work load of the health care professionals and has a negative impact on patient's outcome [3].

The economic load of SSI is mainly due to an increase in the length of hospitalization, additional diagnostic tests, antibiotics, dressings and reoperation in some cases[3,27]. More specifically, a study by Badia *et al.*, (2017) showed that patients who developed SSIs incurred double the medical cost compared to patients who did not develop SSIs. The same study showed that the hospitalization days of the patients with SSI were double the number of days of patients who did not develop SSI[3]. Therefore, the economic impact of SSIs alone makes my study on the patient outcomes, survival and the incidence of SSI's relevant and valuable.

In the aim of this study to compare the total number of general surgery patients with the number of SSI patients over the same 2-year period to determine the rate/incidence of SSI. By comparing the data to be collected on the SSI patients, such as associated factors, outcomes etc. as depicted in the Data Collection Sheet it may be possible to determine the cause of the SSI and the patient survival percentage.

The data of patients who developed SSI in the 2-year period of the study, recording septic markers and vital signs such as temperature, heart rate, white cell count and blood sugar levels before and after the surgical intervention will be collected. As well as record any comorbidities which may have affected the development of SSI in any of these patients. The type of operation, type of perioperative antibiotics and the type of SSI intervention and the patient outcomes will be recorded.

All this data will assist in determining the incidence and outcomes of SSI at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), and possibly shed light on the comorbidities affecting the development of SSI as well as the effectiveness of the patient skin disinfection in theatre and the effectiveness of the antibiotics used peri-operatively at the Charlotte Maxeke Johannesburg Academic Hospital.

Methods

Study type: This is a retrospective study based on morbidity and mortality records on REDCap, hospital files and laboratory results patients of patients who were declared to have had SSI during a 2-year period.

Study setting: Department of Surgery, University of the Witwatersrand circuit at CMJAH.

Study period: Data will be obtained from SSI patient files from the end of June 2018, working backwards to 01 June 2016, which is a 2-year period.

Study population: Records of all patients who were diagnosed with SSIs in the proposed 2-year study period at the Charlotte Maxeke Johannesburg Academic Hospital.

Sample type: The total number of Charlotte Maxeke Johannesburg Academic Hospital, Department of Surgery patients *versus* all Department of Surgery, Charlotte Maxeke Johannesburg Academic Hospital patients who developed SSI over the same period.

Inclusion criteria: Patients who were 18 years and older who developed SSIs.

Exclusion criteria

a) SSI patients on immunosuppressants.
b) Incomplete patient records.

Sample size: The study sample size will be approximately 150 to 250 SSI patient records, since approximately 75 to 125 SSI patients are treated at the Charlotte Maxeke Johannesburg Academic Hospital per year.

Research Questions

What is the incidence and what are the associated factors of SSIs at CMJAH?

Aim and Objectives

Study aim: To determine the rate of occurrence and factors associated with the development of SSI at CMJAH in a 2-year period.

Study objectives

i. To determine the outcomes of the SSI patients, if the patient needed readmission, relook(s), discharged or demised.
ii. To determine the survival rates of patients who developed SSIs.
iii. To determine the rate of occurrence of SSI following surgery at CMJAH.
iv. To determine the demographics and comorbidities of patients who developed SSI.
v. To determine the prevalence of the various types of SSI.
vi. To determine the type of intervention required in patients who developed SSI.

Data Collection and Analysis

Data collection: A ready prepared data collection Excel spread sheet will be used for data entry after extraction from M&M on Research Electronic Data Capture (REDCap) records and patient hospital file records (see attached spread sheet document).

Data analysis: The data will be collected from the REDCap system and from patient hospital file records. A de-identified (anonymous) dataset will be used for data analysis. Data will be summarized and described in the form of tables and graphs, using means, standard deviation, median (range) or frequency. Comparative analysis will be carried out in Stata v13.1 (College Station, Texas) or a similar statistical package using T-tests and Chi-square tests with the level of significance set at $p<0.05$.

Limitations of the Study

Missing data in patient files.
Unavailable biopsy results.

Funding

The project will be funded by the PI personally and the costs to be considered include only stationary such as pens, paper and photocopying.

Ethical Considerations

Ethical approval for this study will be sought from the Human Research Ethics Committee (Medical) in the Faculty of Health Sciences, University of the Witwatersrand.

All data will be kept strictly confidential and will only be released by the laboratory to investigators (the PI and the 3 MMed study supervisors) involved in the study. Data collection will be anonymous. Each patient will be given a unique study number corresponding to the hospital file number which will be recorded on a separate sheet kept separate from the data collection sheets, in a safe locked place only accessible by me. The data collection sheet will not contain any patient identifiers apart from the patient's unique study number.

References

1 Rosenberger LH, Politano AD, Sawyer RG. The surgical care improvement project and prevention of post-operative infection, including surgical site infection. *Surg Infect* (*Larchmt*). 2011; 12(3):163-168.

2 Bull AL, Worth LJ, Spelman T, Richards MJ. Antibiotic Prescribing Practices for Prevention of Surgical Site Infections in Australia: Increased Uptake of National Guidelines after Surveillance and Reporting and Impact on Infection Rates. *Surg Infect (Larchmt).* 2017; 18(7):834-840.

3 Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European Countries. *J Hosp Infect*. 2017 May; 96(1):1-15.

4 Anderson DJ, Epidemiology of surgical site infection in adults up to date. Accessed on 12 Nov. 2017.

https://www.uptodate.com/contents/antimicrobial-prophylaxis-for-prevention-of-surgical-site-infection-in-adults.

5 Alexander JW, Solomkin JS, Edwards MJ. Updated recommendations for control of surgical site infections. *Ann Surg*. 2011; 253(6):1082-1093.

6 Gardner EM, Murasko DM: Age-related changes in Type 1 and Type 2 cytokine production in humans. *Biogerontology*. 2002; 3(5):271-90.

7 Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS Jr: The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. *Infect Control Hosp Epidemiol*. 2001; 22(10):607-12.

8 Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A: Glucose control lowers the risk of wound infection in diabetics after open heart operations. *Ann Thorac Surg*. 1997; 63(2):356-61.

9 Pomposelli JJ, Baxter JK, 3rd, Babineau TJ, Pomfret EA, Driscoll DF, Forse RA, Bistrian BR: Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. *JPEN*. 1998; 22(2):77-81.

10 Raymond DP, Pelletier SJ, Crabtree TD, Schulman AM, Pruett TL, Sawyer RG: Surgical infection and the aging population. *Am Surg*. 2001;67(9):827-32.

11Cheadle WG: Risk factors for surgical site infection. *Surg Infect (Larchmt)*. 2006; 7 Suppl 1:S7-11.

12 Delgado-Rodríguez M, Medina-Cuadros M, Martínez-Gallego G, Sillero-Arenas M: Total cholesterol, HDL-cholesterol, and risk of nosocomial infection: A prospective study in surgical patients. *Infect Control Hosp Epidemiol*. 1997; 18(1):9-18.

13 Anderson DJ, Podgorny K, Berríos-Torres SI, Bratzler DW, Dellinger EP, Greene L, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol*. 2014; 35(6):605-27.

14 Darouiche RO, Wall MJ Jr, Itani KMF, Otterson MF, Webb AL, Carrick MM, et al: Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. *NEJM*. 2010; 362(1):18-26.

15 Milstone AM, Passaretti CL, Perl TM: Chlorhexidine: Expanding the armamentarium for infection control and prevention. *Clin Infect Dis*. 2008; 46(2):274-81.

16 Siribumrungwong B, Chantip A, Noorit P, Wilasrusmee C, Ungpinitpong W, Chotiya P, et al. Comparison of Superficial Surgical Site Infection Between Delayed Primary Versus Primary Wound Closure in Complicated Appendicitis: A Randomized Controlled Trial. *Ann Surg*. 2018; 267(4):631-637.

17 Gandaglia G, Ghani KR, Sood A, Meyers JR, Sammon JD, Schmid M, et al. Comparison of Superficial Surgical Site Infection Between Delayed Primary Versus Primary Wound Closure in Complicated Appendicitis: A Randomized Controlled Trial: *Ann Surg*. 2018; 267(4):631-637.

18 National Nosocomial Infections Surveillance system. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. *Am J Infect Control* 2004; 32(8):470–485.

19 Edwards JR, Peterson KD, Mu Y, Banerjee S, Allen-Bridson K, Morrell G, et al. National Healthcare Safety Network (NHSN) report: Data summary for 2006 through 2008, issued December 2009*. Am J Infect Control*. 2009; 37(10):783-805.

20 National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001. *Am J Infect Control*. 2001; 29(6):404-21.

21 Aziz F, Ferranti K, Lehman EB. Unplanned return to operating room after endovascular repair of abdominal aortic aneurysm (EVAR) is associated with increased risk of hospital readmission. *Vascular.* 2018; 26(2):151-162.

22 Zapata-Copete J, Aguilera-Mosquera S, García-Perdomo HA. Antibiotic prophylaxis in breast reduction surgery: A systematic review and meta-analysis. *J Plast Reconstr Aesthet Surg*. 2017; 70(12):1689-1695.

23 Boonchan T, Wilasrusmee C, McEvoy M, Attia J, Thakkinstian A. Network meta-analysis of antibiotic prophylaxis for prevention of surgical-site infection after groin hernia surgery. *Br J Surg*. 2017; 104(2): e106–e117.

24 Horan TC, Gaynes RP, Martore WJ, Jarvis WR, Emori G. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definition of surgical wound infections. *Infect Control Hosp Epidemiol*. 1992; 13(10):606-8.

25 Ee WWI, Lau WL, Yeo W, Von Bing Y, Yue WM. Does Minimally Invasive Surgery Have a Lower Risk of Surgical Site Infections Compared With Open Spinal Surgery? Clin Orthop Relat Res. 2014; 472(6): 1718–1724.

26 Richmond B, O'Brien B, Ubert A, Thompson S. Current Treatment Guidelines for Postoperative Surgical Site Infection: Clinical Considerations in the Surgical Care Improvement Project Era. *Am Surg*. 2015; 81(4): E179–E180.

27 Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, et al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. *Lancet Infect Dis*. 2016; 16:e276–e287.

Appendix A: Data collection sheet

Data Sheet: "Surgical site infection at a tertiary academic hospital in Johannesburg: a 2 year audit."

Patient Study Number:

Criteria at presentation

Age (years): .....

Gender: Male ☐ Female ☐

Date of admission:

Co-morbidities:

Date of operation:

Type of operation:

Type of SSI:

Blood test results

Parameter	Pre-operative	Post-operative
i. Highest WCC:		
ii. Highest CRP:		
iii. Highest blood sugar:		
iv. Worst pH:		

Management:

Number of relooks:

Outcome:

Appendix B: CEO Letter of approval

GAUTENG PROVINCE
HEALTH
REPUBLIC OF SOUTH AFRICA

CHARLOTTE MAXEKE JOHANNESBURG ACADEMIC HOSPITAL

Enquiries:
Ms. N. Mzila
Office of the Clinical Director
Email:Nolwazi.Mzila@gauteng.gov.za
Tell: (011): 488-4812
16th April 2018

Dear Dr. M. Barbakh

STUDY TITTLE: Surgical Infection at a Tertiary Academic Hospital in Johannesburg: An 8 Year Audit

Permission to conduct the above mentioned study is provisional approved. Your study can only commence once Ethics approval is obtained. Please forward a copy of your Ethics Clearance Certificate as soon as the study is approved by the Ethics Committee for the CEO's office to give you the final approval to conduct the study.

Supported / not supported

Dr. M.I. Mofokeng
Clinical Director
DATE: 17/04/2018

Approved / not approved

Ms G. Bogoshi
Chief Executive Officer
DATE: 18.04.2018

Appendix C: Ethics approval

UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

R14/49 Dr Mohammed Barbakh

HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL)

CLEARANCE CERTIFICATE NO. M180945

NAME: (Principal Investigator)	Dr Mohammed Barbakh
DEPARTMENT:	General Surgery Charlotte Maxeke Johannesburg Academic Hospital
PROJECT TITLE:	Surgical site infection at a tertiary academic hospital: a 2 year audit
DATE CONSIDERED:	28/09/2018
DECISION:	Approved unconditionally
CONDITIONS:	
SUPERVISOR:	Prof TE Luvengo
APPROVED BY:	Dr CB Penny, Chairperson, HREC (Medical)
DATE OF APPROVAL:	15/02/2019

This clearance certificate is valid for 5 years from date of approval. Extension may be applied for.

DECLARATION OF INVESTIGATORS

To be completed in duplicate and **ONE COPY** returned to the Research Office Secretary on the Third Floor, Faculty of Health Sciences, Phillip Tobias Building, 29 Princess of Wales Terrace, Parktown, 2193, University of the Witwatersrand. I/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned research and I/we undertake to ensure compliance with these conditions. Should any departure be contemplated, from the research protocol as approved, I/we undertake to resubmit the application to the Committee. **I agree to submit a yearly progress report**. The date for annual re-certification will be one year after the date of convened meeting where the study was initially reviewed. In this case, the study was initially reviewed in **September** and will therefore be due in the month of **September** each year. Unreported changes to the application may invalidate the clearance given by the HREC (Medical).

Principal Investigator Signature Date

PLEASE QUOTE THE PROTOCOL NUMBER IN ALL ENQUIRIES

Appendix D: CDC definition of SSI

Table 1. Summary of CDC definition of SSI.

Superficial Incisional SSI

- Infection occurs within 30 days after the operation;
- infection involves only the skin or subcutaneous tissue; and
- at least 1 of the following:
  - purulent drainage (culture documentation not required);
  - organisms isolated from fluid/tissue of superficial incision;
  - at least 1 sign of inflammation (eg, pain or tenderness, induration, erythema, local warmth of the wound);
  - wound is deliberately opened by the surgeon; or
  - surgeon or attending physician declares the wound infected.

A wound is not considered a superficial site infection if there is:

- a stitch abscess present;
- infection of episiotomy or circumcision site;
- infection of a burn wound; or
- incisional SSI that extends into the fascia or muscle.

Deep Incisional SSI

- Infection occurs within 30 days of operation or within 1 year if an implant is present;
- infection involves deep soft tissues (eg, fascia and/or muscle) of the incision; and
- at least 1 of the following:
  - purulent drainage from the deep incision but without organ/space involvement;
  - fascial dehiscence or fascia is deliberately separated by the surgeon due to signs of inflammation;
  - deep abscess is identified by direct examination, during reoperation, by histopathology, or by radiologic examination; or
  - surgeon or attending declares deep incisional infection is present.

Organ/Space SSI

- Infection occurs within 30 days of operation or within 1 year if an implant is present;
- infection involves anatomic structures not opened or manipulated by the operation; and
- at least 1 of the following:
  - purulent drainage from a drain placed by a stab wound into the organ/space;
  - organisms isolated from organ/space by aseptic culturing technique;
  - identification of abscess in the organ/space by direct examination, during reoperation, or by histopathological or radiological examination; or
  - diagnosis of organ/space SSI by surgeon or attending physician.

Adapted from[16] Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. *Infect Control Hosp Epidemiol*. 1992;13(10):606-608.

Appendix E: Turn-it-in report

08901071:Barbakh_for_Turnitin_17_Feb_2020.docx

by Marietha Nel

Submission date: 17-Feb-2020 10:15AM (UTC+0200)
Submission ID: 1258823512
File name: db9-447f-972e-3a19836efc22_Barbakh_for_Turnitin_17_Feb_2020.docx (55.01K)
Word count: 2205
Character count: 11385

08901071:Barbakh_for_Turnitin_17_Feb_2020.docx

ORIGINALITY REPORT

8%	2%	1%	4%
SIMILARITY INDEX	INTERNET SOURCES	PUBLICATIONS	STUDENT PAPERS

PRIMARY SOURCES

1	Submitted to University of Cape Town Student Paper	4%
2	Samy Bouaicha, Samuel Blatter, Beat K. Moor, Katharina Spanaus, Claudio Dora, Clément M. L. Werner. "Early Serum Procalcitonin Level after Primary Total Hip Replacement", Mediators of Inflammation, 2013 Publication	1%
3	www.ruralwonca2009.org Internet Source	1%
4	livrepository.liverpool.ac.uk Internet Source	<1%
5	www.tandfonline.com Internet Source	<1%
6	www.urotoday.com Internet Source	<1%

World Journal of Surgery Instructions to authors:

Publishes original articles that offer significant contributions to knowledge in the broad fields of clinical surgery, innovative developments in surgery, global surgical practice and economics, surgical education, rural surgery and surgical history. *WJS* welcomes predominantly human research, including clinical research, outcomes, and health service research. Laboratory research will be published only if it is highly significant and with clear and immediate translational potential to surgical care. *WJS* has an international circulation and is designed to serve as a medium for rapid dissemination of new and important information about the science and art of surgery throughout the world. In the interests of a wide international readership, use of the English language is required. Articles that are accepted for publication are done so with the understanding that they, or their substantive contents, have not been and will not be submitted to any other publication.

PLEASE NOTE: *World Journal of Surgery* does not accept Case Reports and Book Reviews for review or publication. *WJS* will consider publication without prior invitation the following types of manuscripts:

Original Scientific Reports (including Papers Presented at Surgical Conferences): Original Scientific Reports are full-length reports of original basic or clinical investigations. Original Scientific Reports must adhere to a 2,500 word limit (not including the title page, abstract, references, tables, and figures). The final word count should be included in the title page of the manuscript. All clinical trials must be registered through a public trials registry that is acceptable to the International Committee of Medical Journals Editors (ICMJE). For information on ICMJE's statement to register clinical trials, please go to http://www.icmje.org/recommendations/browse/publishing-andeditorial-issues/clinical-trial-registration.html . The trial registration number and agency should be listed on the title page and at the end of the abstract. Randomized clinical trials should be reported following the CONSORT criteria and provide a completed checklist and flow diagram upon manuscript submission. For information on CONSORT and to download the CONSORT checklist and flow diagram, please go to **http://www.consortstatement.org/**.

Original Scientific Reports with Video: *WJS* also seeks original basic or clinical investigation manuscripts that contain brief video clips of surgical techniques or operative findings. Please see the "**MULTIMEDIA MANUSCRIPT SUBMISSION**" below for submitting video augmented manuscripts. For manuscript formatting, please follow the requirements listed above "Original Scientific Reports."

Scientific Reviews (Systematic Reviews and Meta-analyses): Systematic reviews and meta-analysis of the literature are of interest to the journal, and will be handled with the standard peer review process. These reviews should not exceed 3,000 words, should have less than 75 references, and should contain no more than 5 figures or tables. Additional tables and figures can be submitted as supplementary information. Guidelines and a checklist for composing systematic reviews and meta-analysis can be found at: **http://www.prisma-statement.org/**. Please do not submit such reviews without consulting these guidelines and completing the PRISMA checklist.

Innovative Techniques in Surgery Around the World: The WJS in interested in publishing high quality descriptions of innovative surgical techniques that have the potential to improve the quality or efficiency of care. While techniques with universal appeal are most sought after, novel techniques that allow broader access to care in resource challenged environments are also desirable. The successful manuscript will contain a detailed description of the technique and be richly illustrated with figures, and/or video. Line drawings are much superior to intraoperative photos, generally. A brief description of the authors experience with the technique should also be included, if possible. Qualifying manuscripts should be less than 1250 words, have no more than 3 authors, have no more than 5 references, and no more than 8 figures/video segments. A brief unstructured abstract is also required. Please see our instructions for submitting streaming video, below.

[2]

Surgery in Low and Middle Income Countries: *WJS* seeks high quality manuscripts describing the unique problems and unique solutions facing surgeons in rural and impoverished settings, globally. *WJS* requires that manuscripts that use primary data from a low- or middle-income country should include one or more local co-authors. A local co-author is defined as a national of that country who is living and working in their home country. All other author requirements need to be met for the author(s) from the low and middle income country. The editors understand that there may be extenuating circumstances in which this requirement cannot be met. In such cases, a cover letter should explain why a local co-author is not included. Further details on this editorial policy can be found at:

World J Surg (2011) 35:2367–2368.

Cost-effectiveness research is especially valuable for the field of global surgery. However, unless the methods are sound, findings can sometimes be erroneous. *WJS* calls upon authors who undertake cost-effectiveness research in global surgery to review the methodologic points brought out by the following article when they

develop, conduct, and write up their studies: World J Surg. 2017 Jan 19. DOI: 10.1007/s00268-017-3875-0 PMID: 28105528.

WJS also requires completion of the checklist contained in the above article at the time of submission of cost effectiveness studies. The checklist is available at: https://scholar.harvard.edu/shrime/cost-effectiveness-analysischecklist.

If the authors feel another checklist is more suitable for their particular study, they may use that checklist. In all cases of cost-effectiveness studies, the checklist used should be stated in the cover letter and the completed checklist attached to the cover letter.

Letter to the Editor: Letters should pertain to material previously published in *WJS*. Letters should not exceed 500 words with no more than five references, the first of which should be the article on which you wish to comment.

The title must include the words "Letter to the Editor" followed by the full title of the original article that is being referenced in the letter. Please follow this format to structure the title for your Letter to the Editor:

Letter to the Editor: [include the full title of the original article that is being referenced].

Surgical History: Surgical History manuscripts describe either a surgical practice or pioneering surgeon that helped to help reshape the practice of surgery.

WJS will also consider for publication the following types of manuscripts by invitation only:

• Editorial Perspective
• Commentary
• Surgical Symposium Contribution
• Reply, Letter to the Editor: The title must include the words "Author's Reply" followed by the full title of the original article that is being referenced in the reply. Please follow this format to structure the title for your Reply: **Authors' Reply: [full title of the original article that is being referenced]**

All manuscripts must be submitted online to *WJS* via the ScholarOne Manuscripts website (formerly Manuscript Central). Please login directly onto the site at **http://mc.manuscriptcentral.com/*WJS*** and upload your manuscripts following the instructions given on the screen. Authors should keep copies of all manuscript files. WJS accepts no responsibility for files that are lost or destroyed due to electronic problems. Upon manuscript submission, the Editorial Office will review all manuscript files to verify that guidelines and policies stated in this document are adhered to. Your manuscript will be unsubmitted if it does not meet the proper submission requirements.

Authors entering the ScholarOne Manuscripts website can either create a new account or use an existing one. If you have an existing account, please use it for all your submissions and you can track their status on the same page. If you are unsure about whether or not you have an account, or have forgotten your password, enter your email address into the "Password Help" section. You will then receive an automatic e-mail with a new password [3] which you will be prompted to change after logging in. Otherwise please create a new account and then follow the instructions given on the screen. Once you have logged into your account, ScholarOne Manuscripts will lead you through the submission process in a step-by-step orderly process. If you cannot finish your submission in one visit, you can save a draft and re-enter the process at the same point for that manuscript. At any point during this process, there are Help buttons available to see common questions and a support link to ask a specific question via email. After submission, you may return periodically and monitor the progress of your submission through the review process. Authors should go to **https://mc.manuscriptcentral.com/wjs** and click on "System Requirements" for the most updated list of system and browser requirements that should be used with ScholarOne Manuscripts.

Upon manuscript submission in the ScholarOne Manuscripts website, authors will be required to enter the following information:

• Selection of the appropriate manuscript type
• Full title of the manuscript
• Structured abstract (up to 250 words)
• Selection of the appropriate keywords associated with the manuscript
• Names and details of all contributing authors [i.e., e-mail, first name, middle initial(s), surname, degree(s); the departmental and institutional affiliation(s); complete street or mailing address for each affiliation, including the city, state or province, and country where the work was performed].

If you are unable to submit your manuscript via the ScholarOne Manuscripts website or have any questions about *WJS*, please contact the editorial office:

Julie Ann Sosa, MD, Editor-in-Chief
World Journal of Surgery Editorial Office
2541 SW Montgomery Drive
Portland, Oregon 97201-1751

Tel: (971) 275-2918
Fax: (503) 274-9433
E-mail: **worldjsurg@ohsu.edu**

General instructions:
• Use a normal, plain font (e.g., 10-12 point Times Roman or Arial) for text
• Double-space the text
• Use italics for emphasis
• Include page numbers
• Do not use field functions
• Use tab stops or other commands for indents, not the space bar
• Use the table function, not spreadsheets, to make tables
Manuscript style and text formatting: Styling and text formatting refers to the use of special effects to enhance the appearance of the published article. Please make note of the following "Dos and Don'ts" regarding styling:
• **DO** enter all lists as single column lists.
• **DO** use your word processing features to indicate bold, italic, superscript, and subscript text within a
• paragraph or heading.
• **DO NOT** center text for headings. All text should be justified left, with ragged (unjustified) right margins.
• **DO NOT** use italic, underline, or other type effects for the entire text of a heading.
• **DO NOT** use all capital letters for a heading; use initial caps instead. [4]
• **DO NOT** use multiple spaces to set up columns or tables; use tabs instead.
• **DO NOT** use carriage returns at the end of each line of text (use the word wrap feature).
Manuscript organization: Manuscripts should be organized and follow the sequence as indicated below:
TITLE PAGE: The title page should include:
• A concise and informative title
• The name(s) of the author(s) including the affiliation(s) and address(es) of each author. The complete name and address of the author to whom correspondence should be sent, as well as his/her phone number, fax number, and email address.
• A short title for use as a running head.
• Keywords: 2-3 keywords relevant to the manuscript
• Trial registration number for randomized clinical trials (see “Types of Manuscripts: Original Scientific Reports” above)
• Grant support for the research reported
• Statements to comply with ethical requirements (see “Compliance with Ethical Requirements” below for more details):
○ A statement for each author in the manuscript must be included declaring whether there are any conflicts of interest in the manuscript. Even if there is no conflict of interest, this should also be explicitly stated as none declared on the title page.
○ Statement of informed consent should be included if individual participants are included in the study. For example: “Informed consent was obtained from all individual participants included in the study.”
○ Statement of human and/or animal rights should be included (if applicable) stating that the study was approved by the appropriate institution and/or national research ethics committee
• Manuscript word count
ABSTRACT (if applicable): The abstract must appear between the title page and the Introduction section of the manuscript, even if it has been uploaded separately. Manuscripts that require an abstract should contain a structured abstract of not more than 250 words. It should be a factual description of the study performed organized with the headings of *Background* (includes aims, hypotheses, or objectives), *Methods* (includes patient population, procedures, and data analysis), *Results*, and *Conclusions*. The abstract should contain the data to support the key findings or conclusions of the study. The trial registration number for randomized clinical trials must be included at the end of the abstract. The first time an abbreviated term is used, spell it out in full and follow with the abbreviation in parentheses – for example: ultrasound (US).
TEXT: Original Scientific Reports should be arranged in sections titled Introduction, Material and Methods, Results,and Discussion.
1. Introduction: conveys the background and purpose of the report
2. Material and Methods
3. Results & Discussion
When required by the nature of the report, manuscripts that do not follow this specific format may be accepted.

ACKNOWLEDGEMENTS: A brief statement should acknowledge individuals, other than authors, who were of direct help in the reported work or if the work was supported by a federal or commercial grant. All acknowledged persons should give their written consent to being named in the manuscript. This consent is to be uploaded upon manuscript submission.

REFERENCES: Reference citations in the text should be identified by numbers in brackets (e.g. [4]). Number the references in order of their first appearance in the text (not alphabetically). Once a reference is cited, all subsequent citations should be to the original number. References may not appear in your Reference List unless [5] they have been cited in the text or tables. Manuscripts that have been accepted for publication or are in press may be listed as references, but the Journal does not reference unpublished data and personal communications. Use the form for references adopted by the U.S. National Library of Medicine, as in Index Medicus. For each reference, show inclusive page ranges (e.g., 7-19).

In references to journal articles, please include (1) surname and initials (without periods) of the first three authors and et al for all others, (2) the year in parentheses, (3) title of article. (4) abbreviated Journal name, (5) volume number, and (6) inclusive page numbers, in that order. An example follows:

1. Honda T, Nozaki M, Isono N, et al (2001) Endoscope-assisted facial fracture repair. World J Surg 25:1075-1083

In references to books, please include (1) surname and initials (without periods) of the first three authors and et al. for all others, (2) chapter title, if any, (2) chapter title, if any, (3) the year in parentheses, (4) editor(s), if any, (5) title of book, (6) publisher, (6) city of publication, and (7) inclusive page numbers. Volume and edition numbers, and name of translator should be included when appropriate. Examples follow:

1. Harlan BJ, Starr A, Harwin FM, Anesthesia for cardiac surgery (1996) In: Illustrated Handbook of Cardiac Surgery, Springer-Verlag, New York, p. 6-12
2. Jones MC, Smith RB, Treatment of gastric cancer (1976) In: Ford TL (ed) Cancer of the Digestive System, Springer-Verlag, Berlin, p. 140-154

TABLES:

• All tables are to be numbered using Arabic numerals
• Tables should always be cited in text in consecutive numerical order
• For each table, please supply a table heading
• The table title should explain clearly and concisely the components of the table
• Identify any previously published material by giving the original source in the form of a reference at the end of the table caption
• Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body

ARTWORK:

Electronic Figure Submission

• Supply all figures electronically
• Indicate what graphics program was used to create the artwork
• For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MS Office files are also acceptable.
• Vector graphics containing fonts must have the fonts embedded in the files
• Save and name your figure files with “Fig” and the figure number (e.g., Fig1.eps)

Line Art

• Definition: Black and white graphic with no shading
• Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size
• All lines should be at least 0.1 mm (0.3 pt) wide
• Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi

Halftone Art

• Definition: Photographs, drawing, or paintings with fine shading, etc.
• If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.

[6]

• Halftones should have a minimum resolution of 300 dpi

Combination Art

• Definition: a combination of halftone and line art (e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.)
• Combination artwork should have a minimum resolution of 600 dpi

Color Art

• Color art is free of charge for online publication
• If black and white will be shown in the print version, make sure that the main information will still be

visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
• If the figures will be printed in black and white, do not refer to color in the captions.
• Color artwork should be submitted as RGP (8 bits per channel).

Figure Lettering

• To add lettering, it is best to use Helvetica or Arial (san serif fonts)
• Keep lettering consistently sized throughout your final-sized artwork, usually about 2-3mm (8-12 pt).
• Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
• Avoid effects such as shading, outline letters, etc.
• Do not include titles or captions into your illustrations

Figure Numbering

• All figures are to be numbered using Arabic numerals
• Figure parts should be denoted by lowercase letters (a, b, c, etc.)
• Figures should always be cited in text in consecutive numerical order
• If an appendix appears in your manuscript and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.

Figure Captions

• Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
• Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
• No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
• Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
• Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption

Figure Placement and Size

• When preparing your figures, size figures to fit in the column width.
• For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.

Accessibility (in order to give people of all abilities and disabilities access to the content of your figures, please make sure of the following)

• All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware) [7]
• Patterns are used instead or in addition to colors for conveying information (color-blind users would then be able to distinguish the visual elements)
• All figure lettering has a contrast ratio of at least 4.5:1

MULTIMEDIA MANUSCRIPT SUBMISSION:

• A Multimedia manuscript is an article with imbedded video material. Up to 3 videos per manuscript submission will be accepted. All standard instructions for Audio, Video, and Animations should be followed for Multimedia Manuscript Submissions.
• The content of these files must be identical to that reviewed and accepted by the editors of *World Journal of Surgery*
• All narration should be in English.
• Generally, the video clip is used to support the technique description. Additional data regarding the results of the procedure described should be included with the manuscript.

ELECTRONIC SUPPLEMENTARY MATERIAL:

Submission

• Supply all supplementary material in standard file formats.
• Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
• To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.

Audio, Video, and Animations

• Resolution: 16:9 or 4:3
• Maximum file size: 25 GB

• Minimum video duration: 1 sec
• Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp

Text and Presentations

• Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
• A collection of figures may also be combined in a PDF file.

Spreadsheets

• Spreadsheets should be converted to PDF if no interaction with the data is intended.
• If the readers should be encouraged to make their own calculations, spreadsheets should be submitted as .xls files (MS Excel).

Specialized Formats

• Specialized formats such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

Collecting Multiple Files

• It is possible to collect multiple files in a .zip or .gz file.

Numbering

• If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.
• Refer to the supplementary files as "Online Resource", e.g., "... as shown in the animation (Online Resource 3)", "... additional data are given in Online Resource 4".
• Name the files consecutively, e.g. "ESM_3.mpg", "ESM_4.pdf".

[8]

Captions

• For each supplementary material, please supply a concise caption describing the content of the file.

Processing of supplementary files

• Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.

Accessibility

In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that

• The manuscript contain a descriptive caption for each supplementary material
• Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

ABBREVIATIONS, DRUG AND PRODUCT NAMES, DIGITS: Please use the standard abbreviations and units listed in Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers, Sixth Edition (Reston, Va., Council of Biology Editors, 1994). The first time an abbreviated term is used, spell it out in full and follow with the abbreviation in parentheses – for example: ultrasound (US).
Generic names for drugs and chemicals should be used the first time the drug or chemical is mentioned in the text and, preferably, thereafter. The first reference to a drug or chemical in the text should be followed by the manufacturer name, city, state or province, and country – and, if you wish, the trade name – in parentheses.
Please express digits as numerals except when they are the first word in a sentence. Decimals should be written in North American format. Express units of measurement in the metric system whenever possible, and abbreviate them when used with numbers.

If you include figures, tables, or text passages that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online formats. Any material received without such evidence will be assumed to originate from the authors. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used. Any reuse of published material must acknowledge the original source and cited within the manuscript.

Uniform, defined reporting of the sex used for all human, animal, tissue, and cell research should be included in your manuscript. If only one sex is studied, authors must include a justification statement as to why a single-sex study was conducted. WJS also will require sex-based reporting and analysis of data. The full statement was published online in WJS on June 12, 2018 and is available at https://link.springer.com/article/10.1007/s00268-018-4695-6.

WJS requests that all authors comply with the journal's ethical policies below.

Conflict of Interest: Authors must disclose all relationships or interests that could have direct or potential

influence or impart bias on the work. In addition, interests that go beyond financial interests and compensation that may be important to readers should be disclosed. ***EACH author must complete a Conflict of Interest form. The recommended form to use can be downloaded at: http://www.icmje.org/conflicts-of-interest/. The corresponding author should then collect the completed forms from all authors and upload them together at the***
time of submission. Please also make sure to include a conflict of interest disclosure statement for each author on the title page of the manuscript. Examples of disclosure statements: [9]

Funding Funding: This study was funded by X (grant number X).
Conflict of Interest Conflict of Interest: Author A has received research grants from Company X.
Author B has received a speaker honorarium from Company Y and owns
stock in Company Z. Author C is a member of Committee D.
If no conflict exists, the author should state this also.
Conflict of Interest: The authors declare that they have no conflict of interest.
Statement of Informed Consent: All individuals have individual rights that are not to be infringed. Authors are responsible for obtaining informed consent from all individual participants in writing prior to inclusion in the study.
Authors must include a statement of informed consent on the title page of the manuscript. Examples of informed
consent statements:

Informed Consent Informed consent: Informed consent was obtained from all individual participants included in the study.
If identifying information about participants is available in the article
Informed consent: Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.
Statement of Human and Animal Rights: When reporting studies that involve human participants, authors should include a statement that the studies have been approved by the appropriate institution review board (IRB) and/or national research ethics committee. When reporting experiments on animals, authors should indicate whether the international, national, and/or institutional guidelines for the care and use of animals have been followed, and that the studies have been approved by a research ethics committee at the institution or practice at which the studies were conducted.
Authors should include a statement of human and animal rights in the Material and Methods
section as well as on the title page of the manuscript.
Please refer to https://www.springer.com/us/authors-editors/journal-author/journal-author-helpdesk/publishingethics/
14214 for further details on the above ethical policies along with sample forms and statements.

The editorial staff will examine the manuscripts and will customarily send them to appropriate experts. Authors will be notified as to the acceptability of a manuscript as rapidly as possible. All manuscripts will be put through iThenticate, an online plagiarism detection tool comparing the manuscript against previously published scientific work in other journals. If any misconduct is detected, the editorial office will contact the author(s) concerning next steps and actions.

Upon acceptance of your article, the corresponding author will receive an email with a link to the special author query form called “MyPublication” at Springer’s web page where he/she can sign the Copyright Transfer Statement online and indicate whether they wish to order Springer Open Choice*, offprints, etc. Once the MyPublication form has been completed, the manuscript will be processed and the proofs will be sent to the corresponding author. The corresponding author (on behalf of all the authors) will be asked to transfer copyright of the article to the International Society of Surgery (and granting the Publisher exclusive publication and dissemination rights).
This will ensure the widest possible protection and dissemination of information under copyright laws.
[10]
**Springer Open Choice: In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer now provides an alternative publishing option: Springer Open Choice. A*
Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink. In opting for Springer Open Choice, the article will be published as fully open access and the author(s) agree to publish the article under the Creative Commons Attribution License. Please go to http://springer.com/openchoice for more information. Article processing charges (APCs) vary by journal - view the full list at https://www.springernature.com/de/open-research/journalsbooks/

journals.

AUTHOR PROOFS

After a submission is accepted and processed through production, a proof of the article is made available to the corresponding author. The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. It is particularly important to check the proofs for accurate spelling of the author's names and affiliations. It will be impossible to change an incorrectly spelled author's name after publication. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor-in-Chief. Please note that the corresponding author will only receive one proof for review. Revised proofs are provided only upon request of the corresponding author. The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI (Digital Object Identifier). After online publication, further changes can only be made in the form of a Correction (i.e., Erratum), which will be hyperlinked to the article. After release of the online and printed issue, the article can also be cited by issue and page numbers.

VISUAL ABSTRACTS

At the Editor-in-Chief's discretion, selected articles that are published online may be used and presented as a visual abstract. Author(s) may or may not receive advance notice if their article is selected. Visual abstracts are a visual summary of the information contained within an abstract and is meant to convey the key findings of the article. However, it is not meant to replace or substitute the full article. We encourage the use of visual abstracts as a way to disseminate scientific research to a broader audience. The visual abstract may be shared via social media (such as Twitter and Linked in), and will be tweeted via the WJS Twitter account (@worldjsurg).

Increasing problems of duplicate and fraudulent submissions and publications have prompted the editors of surgical journals, including *World Journal of Surgery*, to support these overall principles of publication:

Duplicate Submission and Publication

In general, if a manuscript has been peer-reviewed and published, any subsequent publication is duplication. Exceptions to this general rule may be:

a) Prior publication in meeting program abstract booklets or expanded abstracts such as those published by the Surgical Forum of the American College of Surgeons or Transplantation Proceedings. However, these must be referenced in the final manuscript.

b) A manuscript which extends an original database (a good rule might be expansion by 50% or more) or which analyzes the original database in a different way in order to prove or disprove a different hypothesis. Previous manuscripts reporting the original database must, however, be referenced.

c) Manuscripts which have been published originally in non-English language journals, provided that the prior publication is clearly indicated on the English language submission and referenced in the manuscript. In some circumstances, permission to publish may need to be obtained from the non- English language journal.

For example, any submission duplicating material previously published in full in "Proceedings" or book chapters is considered duplicate unless the exceptions in (a) above apply. Similarly, manuscripts dealing with subgroups of [11] data (i.e., patients) that have previously been analyzed, discussed and published as a larger group are considered duplicate unless (b) above applies.

The Internet raises special concerns. If data have previously appeared on the Internet, submission of those data for publication is considered duplication. If Internet publication follows journal publication, the journal publication should be clearly referenced. Some journals may provide early Internet publication of accepted peer reviewed papers which are subsequently published in that journal. This does not constitute duplication if both manuscripts are identical and covered by the same single copyright.

Fraudulent Publication

The following activities are examples of fraudulent publication practices:

a) Willful and knowing submissions of false data for publication.

b) Submission of data from sources not the author's (or authors') own.

c) Falsely certifying that the submitted work is original and has not been submitted to, or accepted by, another journal.

d) Sponsoring or vouching for a manuscript containing data over which the sponsor has no control or knowledge.

e) Allowing one's name to appear as an author without having contributed significantly to the study.

f) Adding an author's name to a manuscript to which he/she has not contributed, or reviewed or agreed to in its current form.

g) Flagrant omission of reference to the work of other investigators which established their priority.

h) Falsification of any item on the copyright form.

i) Failure to disclose potential conflict of interest with a sponsoring agency.

While not intended as an all-inclusive document, these examples and guidelines should alert authors to potential

problems that should be avoided when they are considering submission of a manuscript to a peer-reviewed journal.

Surgery Journal Editors Group Consensus Statement on the Adoption of the COPE Guidelines

We, the undersigned member journals of the Surgery Journal Editors Group (SJEG), in the furtherance of integrity in surgical and scientific publication, agree to adopt the guidelines established by the Committee on Publication Ethics (COPE)[1]. The COPE guidelines represent a means of addressing a variety of ethical concerns, including duplicate publication and authorship misconduct issues, which have, unfortunately, become more prevalent.

[1]*COPE Committee on Publication Ethics. https://publicationethics.org/resources/guidelines*

In the majority of clinical and research studies submitted to surgery journals for possible publication, many individuals participate in the conception, execution, and documentation of each of those works. However, recognition of work in the form of authorship has varied widely. This consensus statement is being issued to clarify and define the criteria for surgical journal authorship.

The following guidelines should be used to identify individuals whose work qualifies them as authors as distinct from those who are contributors to the work under consideration. All persons designated as authors should qualify for authorship, and all those who qualify should be so credited.

A. Authorship Criteria

Individuals claiming authorship should meet all of the following 3 conditions:

1. Authors make substantial contributions to conception and design, and/or acquisition of data, and/or analysis and interpretation of data;
2. Authors participate in drafting the article or revising it critically for important intellectual content; and [12]
3. Authors give final approval of the version to be submitted and any revised version to be published.

Each author should have participated sufficiently in the work to take public responsibility for appropriate portion of the content. Allowing one's name to appear as an author without having contributed significantly to the study or adding the name of an individual who has not contributed or who has not agreed to the work in its current form is considered a breach of appropriate authorship.

Acquisition of funding, collection of data, contributing cases, or general supervision of the research group, of itself, or just being the Chair of the department does not justify authorship if the above criteria are not fulfilled.

B. Order of Authors

The order of authorship on the byline should be a joint decision of the co-authors. Authors should be prepared to explain the order in which authors are listed.

C. Multi-Center Studies

When a large, multi-center group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship defined above and editors will ask these individuals to complete journal-specific author and conflict of interest disclosure forms. When submitting a group-author manuscript, the corresponding author should clearly indicate the preferred citation and should clearly identify all individual authors as well as the group name.

D. Contributors Listed in Acknowledgments

All contributors who do not meet the criteria for authorship should be listed in an acknowledgments section. Examples of those who might be acknowledged include: individuals who allowed their clinical experience (i.e., cases) to be included, a person who provided purely technical help, writing assistance, or a department Chair who provided only general support. Financial and material support should also be acknowledged.

Groups of persons who have contributed materially to the paper but whose contributions do not justify authorship may be listed under a heading such as "collaborators" or "clinical investigators" or "participating investigators," and their function or contribution should be described - for example, "served as scientific advisors," "critically reviewed the study proposal," "collected data," or "provided and cared for study patients." Because readers may infer their endorsement of the data and conclusions, all persons listed as contributors must give written permission to be acknowledged.

E. In Conclusion

This consensus statement is intended as a basic guide for authors. In the interest of promoting the highest ethics in surgical publishing and the surgical sciences, we ask that authors take these criteria into careful consideration when submitting a manuscript to a peer-reviewed surgical journal.

F
FACULTY OF HEALTH SCIENCES
WITS UNIVERSITY

Department of Surgery

7 York Road, Parktown, 2193 South Africa • Telegrams "Witsmed" • Telephone (011) 717-2000 • Fax (011) 484-2717

22 February 2022

Letter to the Editor,

Please find attached our manuscript entitled: “Surgical site infection at a tertiary academic hospital in Johannesburg: A one-year audit” for consideration of publication in the prestigious World Journal of Surgery.

This article has not been submitted for consideration of publication elsewhere.

The study was done in order to address a gap in the knowledge on surgical site infection type and prevalence in a big public hospital. The Charlotte Maxeke Johannesburg Academic Hospital is situated in the Gauteng Province of South Africa. The healthcare system in South Africa (a third world country) is financially greatly under resourced and surgical site infections increases this burden. Other prevalent comorbidities such as hypertension, diabetes mellitus, HIV/AIDS impact negatively on patient morbidity, increasing the medical costs even more.

This study revealed a low incidence of surgical site infections at 4.8% comparable to Norway and Switzerland but in contrast to other African countries. A high infection rate was seen in this study in patients younger than 40 years, which could be due to the high number of emergency cases often driven by violence injuries.

In contrast to most studies reported in the literature, gram-negative organisms were found to be the most common cause of surgical site infections in this hospital. Although postoperative

surgical site infections are associated with longer hospital stay (19 days) and readmission cases from home are common, the mortality rate is low.

Kindly contact the corresponding author if there are further questions or comments.

With kindest regards,

Corresponding author:

Mohammed K E Barbakh

E-mail address: mohamekhaled12@yahoo.com

Cell: +27767707548

Author Contribution Statement and Agreement of Co-authors

Title of manuscript: Surgical site infection at a tertiary academic hospital in Johannesburg: A one-year audit

Name of corresponding author: Dr Mohammed K E Barbakh

Herewith all 4 authors declare that each author had made a significant contribution to this manuscript as detailed below, have seen and approved the final manuscript and have agreed to its submission to World Journal of Surgery.

None of the authors have any conflict of interest.

Dr Mohammed K E Barbakh

Execution of research work, collection and analysis of data, drafting the manuscript, final corrections and approval of the final manuscript.

22 Feb 2022

Professor Thifheli Luvhengo

Original study idea, conceptual design, clinical supervision and final approval of the manuscript.

22 Feb 2022

Professor Adelin Muganza

Clinical supervision of project and final approval of the manuscript.

22 Feb 2022

Dr Marietha Nel

Research design, academic supervision, final writing, proofreading and editing of the manuscript.



22 Oct 2022